General Info

Sanaria Inc. is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Plasmodium falciparum malaria is responsible for more childhood mortality than any other single infectious agent. The firm s vaccine development efforts are focused on African children, the population most urgently in need of protection. Based in Rockville, Md., it houses a custom-designed and constructed dedicated clinical manufacturing facility for producing its attenuated malaria parasite vaccine. Sanaria Inc. has two ongoing Cooperative Research and Development Agreements (CRADAs) with U.S. government laboratories, a development contract with a biotechnology company, a funded research agreement with a nonprofit, and a services agreement with a nonprofit research institute and a government laboratory.